SEXUAL FEATURES OF SCHIZOPHRENIA: FOCUS ON PSYCHOENDOCRINOLOGY


Cite item

Full Text

Abstract

The data on the effect of sexual characteristics on the course of the disease and therapy for schizophrenia are presented. The “estrogen protection hypothesis” is being discussed, including the role of estrogens in men vulnerable to schizophrenia. The neuroprotective properties of estrogen are described. Neuroactive steroids testosterone and its predecessors are considered in terms of gender differences at different stages of the course of schizophrenia. Gender-related side effects of antipsychotic therapy, including depending on its type, are highlighted.

About the authors

Natalia N Petrova

Saint Petersburg State University

Email: petrova_nn@mail.ru
Department of Psychiatry and Addictions University Embankment, 7/9, St. Petersburg, 199034

Anastasia I Vasilyeva

1) Psychiatric Hospital of Kaliningrad region №1; 2) Immanuel Kant Baltic Federal University

Email: vasiljeva_anastasija@mail.ru
2) Therapy Department 1) Alexander Nevsky street, 78A, Kaliningrad, Kaliningrad region, 236008; 2) 236016, Kaliningrad, Alexander Nevsky street, 14

References

  1. Вильянов В.Б. Гендерный фактор и эффективность современных антипсихотиков при лечении больных шизофренией // Обозрение психиатрии и клинической психологии им. В.М. Бехтерева. 2004. № 2. С. 18-19.
  2. Горобец Л.Н. Эндокринологические аспекты проблемы переносимости нейролептической терапии у больных шизофренией (возрастные и гендерные факторы) // Психиатрия и психофармакотерапия. Журнал им. П.Б. Ганнушкина. 2012. №14(1). С. 41-47.
  3. Матросова М. И., Горобец Л. Н. Роль половых гормонов в патофизиологии первого эпизода шизофрении // Социальная и клиническая психиатрия. 2011. Т. 21, вып. 4. С. 31-33.
  4. Петрова Н.Н., Воинкова Е.Е., Дорофейкова М.В. Половые особенности первого эпизода шизофрении // Психическое здоровье. 2018. №5. С. 43-51.
  5. Abel K.M., Drake R., Goldstein J.M. Sex differences in schizophrenia // International Review of Psychiatry. 2010. Vol. 22, №5. P. 417-428.
  6. Adams M.M., Fink S.E., Janssen W.G. et al. Estrogen modulates synaptic N-methyl-D-aspartate receptor subunit distribution in the aged hippocampus // Journal of Comparative Neurology. 2004. Vol. 474, №3. P. 419-426.
  7. Arevalo M.A., Santos-Galindo M., Bellini M.J. et al. Actions of estrogens on glial cells: implications for neuroprotection // Biochimica et Biophysica Acta. 2010. №1800 (10). P. 1106-1112.
  8. Arevalo M.A., Santos-Galindo M., Lagunas N. et al. Selective estrogen receptor modulators as brain therapeutic agents // Journal of Molecular Endocrinology. 2011. № 46(1). R1-R9.
  9. Basson B.R., Kinon B.J., Taylor C.C. et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone // J. Clin. Psychiatry. 2001. № 62. P. 231-238.
  10. Behl C. Estrogen can protect neurons: modes of action // Journal of Steroid Biochemistry and Molecular Biology. 2002. №83(1-5). P. 195-197.
  11. Bergemann N., Parzer P., Runnebaum B. et al. Estrogen, menstrual cycle phases, and psychopathology in women suffering from schizophrenia // Psychological Medicine. 2007. №37(10). P. 1427-1436.
  12. Bobes J., Rejas J., Garcia-Garcia M. et al. EIRE Study Group. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study // Schizophr. Res. 2003. №62. P. 77-88.
  13. Boyce P., Barriball E. Puerperal psychosis // Archives of Women’s Mental Health. 2010. №13(1). P. 45-47.
  14. Bryant D.N., Dorsa D.M. Roles of estrogen receptors alpha and beta in sexually dimorphic neuroprotection against glutamate toxicity // Neuroscience. 2010. №170(4). P. 1261-1269.
  15. Choi S.H, Kang S.B., Joe S.H. Changes in premenstrual symptoms in women with schizophrenia: a prospective study // Psychosomatic Medicine. 2001. № 63(5). P. 822-829.
  16. Compton M.T., Miller A.H. Antipsychotic-induced hyperprolactinemia and sexual dysfunction // Psychopharmacolgy. 2002. №36. P. 143.
  17. Cotton S.M., Lambert M., Schimmelmann B.G. et al. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis // Schizophrenia Research. 2009. № 114(1-3). P. 17-24.
  18. Garcia-Segura L.M., Azcoitia I., DonCarlos L.L. Neuroprotection by estradiol // Progress in Neurobiology. 2001. № 63(1). Р. 29-60.
  19. Hafner H. Gender differences in schizophrenia // Psychoneuroendocrinology. 2003. № 28(supplement 2). Р. 17-54.
  20. Hayes N.L. et al. Inflammatory molecular signature associated with infectious agents in psychosis // Schizophrenia bulletin. 2014. № 40(5). Р. 963-972
  21. Horacek J., Bubenikova-Valesova V., Kopecek M. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia // CNS Drugs. 2006. №20(5). Р. 389-409.
  22. Huber T.J., Tettenborn C., Leifke E., Emrich H.M. Sex hormones in psychotic men // Psychoneuroendocrinology. 2005. № 30(1). Р. 111-114.
  23. Hughes Z.A., Liu F., Marquis K. et al. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders // Current Molecular Pharmacology. 2009. № 2(3). Р. 215-236.
  24. Kaneda Y., Ohmori T. Relation between estradiol and negative symptoms in men with schizophrenia // Journal of Neuropsychiatry and Clinical Neurosciences. 2005. № 17(2). Р. 239-242.
  25. Ko Y.H., Joe S.H., Cho W. et al. Estrogen, cognitive function and negative symptoms in female schizophrenia // Neuropsychobiology. 2006. № 53(4). Р. 169-175.
  26. Kumari V., Konstantinou J., Papadopoulos A. et al. Evidence for a role of progesterone in menstrual cycle-related variability in prepulse inhibition in healthy young women // Neuropsychopharmacology. 2010. № 35(4). Р. 929-937.
  27. Li J., Siegel M., Yuan M. et al. Estrogen enhances neurogenesis and behavioral recovery after stroke // Journal of Cerebral Blood Flow and Metabolism. 2011. № 31(2). Р. 413-425.
  28. Liu M., Kelley M.H., Herson P.S., Hurn P.D. Neuroprotection of sex steroids // Minerva Endocrinologica. 2010. № 35(2). Р. 127-143.
  29. Lokuge S., Frey B.N., Foster J.A. et al. The rapid effects of estrogen: a mini-review // Behavioural Pharmacology. 2010. № 21(5-6). Р. 465-472.
  30. MacKenzie E.M., Odontiadis J., Le Mellédo J.M. et al. The relevance of neuroactive steroids in schizophrenia, depression, and anxiety disorders // Cellular and Molecular Neurobiology. 2007. № 27(5). Р. 541-574.
  31. Mahe V., Dumaine A. Oestrogen withdrawal associated psychoses // Acta Psychiatrica Scandinavica. 2001. № 104(5). Р. 323-331.
  32. Maninger N., Wolkowitz O.M., Reus V.I. et al. Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS) // Frontiers in Neuroendocrinology. 2009. № 30(1). Р. 65-91.
  33. Markham J.A. Sex steroids and schizophrenia // Reviews in Endocrine and Metabolic Disorders. 2012. № 13 (3). Р. 187-207.
  34. Marx C.E., Bradford D.W., Hamer R.M. et al. Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence // Neuroscience. 2011. № 191. Р. 78-90.
  35. McGrath J., Saha S., Chant D., Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality // Epidemiologic Reviews. 2008. № 30(1). Р. 67-76.
  36. Melcangi R.C., Panzica G., Garcia-Segura L.M. Neuroactive steroids: focus on human brain // Neuroscience. 2011. №191. Р. 1-5.
  37. Melcangi C.R, Garcia-Segura L.M. Sex-specific therapeutic strategies based on neuroactive steroids: in search for innovative tools for neuroprotection // Hormones and Behavior. 2010. № 57(1). Р. 2-11.
  38. Misiak B., Frydecka D., Loska O. et al. Testosterone, DHEA and DHEA-S in patients with schizophrenia: a systematic review and meta-analysis // Psychoneuroendocrinology. 2018. №89. Р. 92-102.
  39. Morgan V.A., Castle D.J., Jablensky A.V. Do women express and experience psychosis differently from men? Epidemiological evidence from the Australian national study of low prevalence (Psychotic) disorders // Australian and New Zealand Journal of Psychiatry. 2008. № 42(1). Р. 74-82.
  40. Moriarty P.J., Lieber D., Bennett A. et al. Gender differences in poor outcome patients with lifelong schizophrenia // Schizophr. Bull. 2001. № 27. Р. 103-113.
  41. Rao M.L., Kolsch H. Effects of estrogen on brain development and neuroprotection - implications for negative symptoms in schizophrenia // Psychoneuroendocrinology. 2003. № 28(supplement 2). Р. 83-96.
  42. Rao M.L., Kolsch H. Neuroprotective effects of estradiol-17 beta: implications for psychiatric disorders // Arch. Women’s Ment. Health. 2002. № 5(3). Р. 105-110.
  43. Rezin G.T., Amboni G., Zugno A.I. et al. Mitochondrial dysfunction and psychiatric disorders // Neurochemical Research. 2009. № 34(6). Р. 1021-1029.
  44. Riecher-Rossler A., Hafner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry // Acta Psychiatr. Scand. 2000. № 102, Suppl. Р. 58-62.
  45. Riecher-Rossler A., Kulkarni J. Estrogens and gonadal function in schizophrenia and related psychoses // Current Topics in Behavioral Neurosciences. 2011. № 8. Р. 155-171.
  46. Riecher-Rossler A. Oestrogen effects in schizophrenia and their potential therapeutic implications-review // Archives of Women’s Mental Health. 2002. № 5(3). Р. 111-118.
  47. Ritsner M.S. The clinical and therapeutic potentials of dehydroepiandrosterone and pregnenolone in schizophrenia // Neuroscience. 2011. № 191(1). Р. 91-100.
  48. Rubin L.H., Carter C.S., Drogos L. et al. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia // Schizophrenia Research. 2010. № 124(1-3). Р. 13-21.
  49. Rubin L.H., Haas G.L., Keshavan M.S. et al. Sex difference in cognitive response to antipsychotic treatment in first episode schizophrenia // Neuropsychopharmacol Off Publ American College Of Neuropsychopharmacology. 2008. № 33. Р. 290-297.
  50. Sanchez M.G., Bourque M., Morissette M., Di Paolo T. Steroids-dopamine interactions in the pathophysiology and treatment of CNS disorders // CNS Neuroscience and Therapeutics. 2010. № 16 (3). Р. 43-71.
  51. Segal M., Avital A., Berstein S. et al. Prolactin and estradiol serum levels in unmedicated male paranoid schizophrenia // Prog. Neuropsychopharmacol. Biol. Psychiatry. 2007. № 2. Р. 378-382.
  52. Shipman S.L., Baker E.K., Pearlson G., Astur R.S. Absence of established sex differences in patients with schizophrenia on a two-dimensional object array task // Psychiatry Res. 2009. №166. Р. 158-165.
  53. Simpkins J.W., Yi K.D., Yang S.H., Dykens J.A. Mitochondrial mechanisms of estrogen neuroprotection // Biochimica et Biophysica Acta. 2010. № 1800(10). Р. 1113-1120.
  54. Szymanski S., Lieberman J.A., Alvir J.M. et al. Gender differences in onset of illness, treatment response, course, and biological indexes in first-episode schizophrenia patients // Am. J. Psychiatry. 1995. № 152. Р. 698-703.
  55. Taherianfard M., Shariaty M. Evaluation of serum steroid hormones in schizophrenic patients// Indian Journal of Medical Sciences. 2004. № 58(1). Р. 3-9.
  56. Taylor G.T., Maloney S., Dearborn J., Weiss J. Hormones in the mentally disturbed brain: steroids and peptides in the development and treatment of psychopathology // Central Nervous System Agents in Medicinal Chemistry. 2009. № 9(4). Р. 331-360.
  57. Ter Horst G.J. Estrogen in the limbic system // Vitamins and hormones. 2010. №82. Р. 319-338.
  58. Yang L.C., Zhang Q.G., Zhou C.F. et al. Extranuclear estrogen receptors mediate the neuroprotective effects of estrogen in the rat hippocampus // Plos One. 2010. №5(5). e9851. https://doi.org/10.1371/journal.pone.0009851

Copyright (c) 2019 Petrova N.N., Vasilyeva A.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies